EUVIMEDEUVIMED entdecken
Crossref

Growth hormone treatment in children in Israel: A large‐scale retrospective database study

Yael Reichenberg, Rachel Bello, Bernice Oberman, Moryia Cohen, Avner Herman Cohen, Vered Shkalim Zemer iD

Acta Paediatrica · 2025

DOI: 10.1111/apa.17535 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Yael Reichenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dan-Petach Tikva District, Clalit Health Services, Tel Aviv, Israel. Hauptthemen laut MEDLINE: Human Growth Hormone, Growth Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the indications, population characteristics and latency between short stature diagnosis to treatment with recombinant growth hormone (GH) therapy in a large cohort of children in Israel.

Methods

We performed a retrospective medical chart review of all children treated with GH for conditions associated with short stature in three central districts in Israel from 1 January 2010 to 31 December 2021. Data extracted from the medical files included demographics, time to diagnosis, treatment indications and GH therapy duration.

Results

The study group comprised 5148 children aged 1 day to 17 years. A total of 64.1% were diagnosed with idiopathic short stature (ISS), 31.1% with GH deficiency (GHD) and 2.5% with small‐for‐gestational age (SGA). Males were treated more than females (58.9% vs. 41.1%). The mean age at first documentation of short stature was 6.9 ± 3.5 years. GH therapy was initiated at a mean age of 9.8 ± 3.3 years. A total of 51.2% were of high socio‐economic status (SES); 78.2% were non‐ultraorthodox Jews, 13%, ultraorthodox Jews, and 8.8% were Arabs.

Conclusion

Meticulous growth follow‐up from early childhood for all children, specifically females, those of low SES, and minorities is important to provide appropriate referral, treatment and final adult height outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneGrowth DisordersHumansRetrospective StudiesFemaleMaleIsraelChildChild, PreschoolAdolescentInfantInfant, NewbornDatabases, Factual

Stichwörter der Autor:innen

childrengrowth hormone deficiencygrowth hormone treatmentidiopathic short staturesmall‐for‐gestational age

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Dan-Petach Tikva District, Clalit Health Services, Tel Aviv, Israel.
  • Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel.
  • Microbiology Unit, Ariel University, Ariel, Israel.
  • Pediatric Ambulatory Community Clinic, Petach Tikva, Israel.

ORCID-Profile: Vered Shkalim Zemer

Förderung

  • Novo Nordisk

Zitieren

APA

Reichenberg, Y., Bello, R., Oberman, B., Cohen, M., Cohen, A. H., & Shkalim Zemer, V. (2025). Growth hormone treatment in children in Israel: A large‐scale retrospective database study. Acta Paediatrica. https://doi.org/10.1111/apa.17535

Vancouver

Reichenberg Y, Bello R, Oberman B, Cohen M, Cohen AH, Shkalim Zemer V. Growth hormone treatment in children in Israel: A large‐scale retrospective database study. Acta Paediatrica. 2025. doi:10.1111/apa.17535

BibTeX
@article{Reichenberg2025,
  author = {Reichenberg, Yael and Bello, Rachel and Oberman, Bernice and Cohen, Moryia and Cohen, Avner Herman and Shkalim Zemer, Vered},
  title = {Growth hormone treatment in children in Israel: A large‐scale retrospective database study},
  journal = {Acta Paediatrica},
  year = {2025},
  doi = {10.1111/apa.17535}
}
Kostenlos starten →